Journal article icon

Journal article

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease

Abstract:

Susceptibility to multiple autoimmune diseases is associated with common gene polymorphisms influencing IL-2 signaling and Treg function, making Treg-specific expansion by IL-2 a compelling therapeutic approach to treatment. As an in vivo IL-2 half-life enhancer we used a non-targeted, effector-function-silent human IgG1 as a fusion protein. An IL-2 mutein (N88D) with reduced binding to the intermediate affinity IL-2Rβγ receptor was engineered with a stoichiometry of two IL-2N88D molecules pe...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/j.jaut.2018.10.017

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM
Subgroup:
Human Genetics Wt Centre
Role:
Author
Expand authors...
Hoffmann-La Roche, Ltd More from this funder
NIHR Cambridge Biomedical Research Centre More from this funder
Publisher:
Elsevier Publisher's website
Journal:
Journal of Autoimmunity Journal website
Volume:
95
Pages:
1-14
Publication date:
2018-11-13
Acceptance date:
2018-10-22
DOI:
EISSN:
1095-9157
ISSN:
0896-8411
Pubs id:
pubs:946287
URN:
uri:c14bdc45-54bf-47e7-a898-e3126d4bd60a
UUID:
uuid:c14bdc45-54bf-47e7-a898-e3126d4bd60a
Local pid:
pubs:946287

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP